[MO-68] Presentation Awards
Value of Eicosapentaenoic Acid to Arachidonic Acid Ratio Predicts Prognosis of Peripheral Artery Disease Patients Caused by Aortoiliac Artery Lesions
Background
Recent studies reported that value of eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio was good biomarker for risk of coronary artery disease (CAD). However, it is unclear whether the value is useful for predicting prognosis of peripheral artery disease (PAD) patients.
Methods
We retrospectively reviewed consecutive 234 PAD patients caused by aortoiliac artery lesions underwent endovascular therapy (EVT). All of them were divided into two groups using preoperative value of EPA/AA ratio; LOW group with the levels <0.4 (n=149), and HIGH group with the levels ≧0.4 (n=85). The incidence of major adverse limb events (MALE), including target lesion revascularization (TLR), non TLR, and major amputation, and major adverse events (MAE), including MALE and death from any cause, were analyzed.
Results
At a median follow up interval of 36 months, TLR occurred in 12 patients (9 vs. 3, p=0.54), and MALE in 58 patients (41 vs. 17, p=0.21). Conversely, death from any cause occurred in 48 patients (41 vs. 7, p<0.01), and MAE in 94 patients (70 vs. 24, p<0.01). Multivariate Cox regression analysis showed critical limb ischemia (CLI) (hazard ratio [HR]: 3.33; 95% confidence interval [CI]: 1.98 to 5.59; p<0.01) and value of EPA/AA ratio <0.4 (HR: 1.99; 95% CI: 1.21 to 3.26; P<0.01) independently predicted MAE after EVT.
Conclusion
Value of EPA/AA ratio may be candidate for good biomarker for predicting major adverse events of PAD patients after EVT.
Recent studies reported that value of eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio was good biomarker for risk of coronary artery disease (CAD). However, it is unclear whether the value is useful for predicting prognosis of peripheral artery disease (PAD) patients.
Methods
We retrospectively reviewed consecutive 234 PAD patients caused by aortoiliac artery lesions underwent endovascular therapy (EVT). All of them were divided into two groups using preoperative value of EPA/AA ratio; LOW group with the levels <0.4 (n=149), and HIGH group with the levels ≧0.4 (n=85). The incidence of major adverse limb events (MALE), including target lesion revascularization (TLR), non TLR, and major amputation, and major adverse events (MAE), including MALE and death from any cause, were analyzed.
Results
At a median follow up interval of 36 months, TLR occurred in 12 patients (9 vs. 3, p=0.54), and MALE in 58 patients (41 vs. 17, p=0.21). Conversely, death from any cause occurred in 48 patients (41 vs. 7, p<0.01), and MAE in 94 patients (70 vs. 24, p<0.01). Multivariate Cox regression analysis showed critical limb ischemia (CLI) (hazard ratio [HR]: 3.33; 95% confidence interval [CI]: 1.98 to 5.59; p<0.01) and value of EPA/AA ratio <0.4 (HR: 1.99; 95% CI: 1.21 to 3.26; P<0.01) independently predicted MAE after EVT.
Conclusion
Value of EPA/AA ratio may be candidate for good biomarker for predicting major adverse events of PAD patients after EVT.